BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 16406404)

  • 1. Nanodecoy system: a novel approach to design hepatitis B vaccine for immunopotentiation.
    Goyal AK; Rawat A; Mahor S; Gupta PN; Khatri K; Vyas SP
    Int J Pharm; 2006 Feb; 309(1-2):227-33. PubMed ID: 16406404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes.
    Shukla A; Katare OP; Singh B; Vyas SP
    Int J Pharm; 2010 Jan; 385(1-2):47-52. PubMed ID: 19835938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres.
    Feng L; Qi XR; Zhou XJ; Maitani Y; Wang SC; Jiang Y; Nagai T
    J Control Release; 2006 May; 112(1):35-42. PubMed ID: 16516999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chitosan-based nanoparticles for improving immunization against hepatitis B infection.
    Prego C; Paolicelli P; Díaz B; Vicente S; Sánchez A; González-Fernández A; Alonso MJ
    Vaccine; 2010 Mar; 28(14):2607-14. PubMed ID: 20096389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cationic transfersomes based topical genetic vaccine against hepatitis B.
    Mahor S; Rawat A; Dubey PK; Gupta PN; Khatri K; Goyal AK; Vyas SP
    Int J Pharm; 2007 Aug; 340(1-2):13-9. PubMed ID: 17446015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B.
    Jaganathan KS; Singh P; Prabakaran D; Mishra V; Vyas SP
    J Pharm Pharmacol; 2004 Oct; 56(10):1243-50. PubMed ID: 15482638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.
    Jaganathan KS; Vyas SP
    Vaccine; 2006 May; 24(19):4201-11. PubMed ID: 16446012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posintro™-HBsAg, a modified ISCOM including HBsAg, induces strong cellular and humoral responses.
    Schiött A; Larsson K; Manniche S; Kalliomäki S; Heydenreich AV; Dalsgaard K; Kirkby N
    Int J Pharm; 2011 Jul; 414(1-2):312-20. PubMed ID: 21601626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response induced by a different combined immunization of HBsAg vaccine.
    Wu T; Chen M; Ou SH; Cheng T; Zhang J; Xia NS
    Intervirology; 2007; 50(5):336-40. PubMed ID: 17700028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen.
    Borges O; Silva M; de Sousa A; Borchard G; Junginger HE; Cordeiro-da-Silva A
    Int Immunopharmacol; 2008 Dec; 8(13-14):1773-80. PubMed ID: 18801462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elastic liposomes mediated transcutaneous immunization against Hepatitis B.
    Mishra D; Dubey V; Asthana A; Saraf DK; Jain NK
    Vaccine; 2006 May; 24(22):4847-55. PubMed ID: 16600441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigen-loaded modified liposomes.
    Mishra D; Mishra PK; Dubey V; Nahar M; Dabadghao S; Jain NK
    Eur J Pharm Sci; 2008 Apr; 33(4-5):424-33. PubMed ID: 18359615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA.
    Shen E; Li L; Li L; Feng L; Lu L; Yao Z; Lin H; Wu C
    Cell Mol Immunol; 2007 Apr; 4(2):113-20. PubMed ID: 17484805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral protein complexed liposomes for intranasal delivery of hepatitis B surface antigen.
    Tiwari S; Verma SK; Agrawal GP; Vyas SP
    Int J Pharm; 2011 Jul; 413(1-2):211-9. PubMed ID: 21540094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant effect of CIA07, a combination of Escherichia coli DNA fragments and modified lipopolysaccharides, on the immune response to hepatitis B virus surface antigen.
    Song ES; Park SA; Kim SH; Cho YJ; Ahn BY; Ahn BC; Lee NG
    FEMS Immunol Med Microbiol; 2007 Dec; 51(3):496-504. PubMed ID: 17877731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
    Mutwiri G; Benjamin P; Soita H; Babiuk LA
    Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of humoral and cell-mediated immune responses to cationic PLGA microspheres containing recombinant hepatitis B antigen.
    Saini V; Jain V; Sudheesh MS; Jaganathan KS; Murthy PK; Kohli DV
    Int J Pharm; 2011 Apr; 408(1-2):50-7. PubMed ID: 21291968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery.
    Chong CS; Cao M; Wong WW; Fischer KP; Addison WR; Kwon GS; Tyrrell DL; Samuel J
    J Control Release; 2005 Jan; 102(1):85-99. PubMed ID: 15653136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles.
    Borges O; Cordeiro-da-Silva A; Tavares J; Santarém N; de Sousa A; Borchard G; Junginger HE
    Eur J Pharm Biopharm; 2008 Jun; 69(2):405-16. PubMed ID: 18364251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new vaccine adjuvant (BOS 2000) a potent enhancer mixed Th1/Th2 immune responses in mice immunized with HBsAg.
    Khajuria A; Gupta A; Malik F; Singh S; Singh J; Gupta BD; Suri KA; Suden P; Srinivas VK; Ella K; Qazi GN
    Vaccine; 2007 Jun; 25(23):4586-94. PubMed ID: 17498851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.